China Biopharmaceuticals Market By Therapeutic Area (Anti-infective, Cancer, Others.) and Forecast - 2026

Biopharmaceuticals, or biologics, are one of the world's fastest-growing class of medicines: among the top 10 therapeutics available on the market today, eight are biopharmaceuticals. Unlike synthetic drugs, they are called as the products of live organisms and are better targeted to everything from cancer and diabetes to immune disorders, like arthritis. Biopharmaceuticals are going to offer several benefits, including highly effective and potent action, fewer side effects, and the potential to cure diseases actually rather than treat the symptoms merely, which have significantly increased the biopharmaceutical products demand in the market. China is known to be a relative newcomer to the biopharmaceutical industry. Biological therapeutics have been on the market only since the 1990s by multinational corporations in China, but the country has been making significant and rapid progress ever since.

Market Overview

China is known to be the world's second largest pharmaceutical market after the US and is expected to overtake the US by 2020. The biopharmaceutical industry is china’s thriving sector, is forecasted to grow to about 15% of GDP in 2030, and thus becoming an important economic growth point. China is moving from firstly a generic market to a global biopharmaceutical market. The Chinese biopharmaceutical industry is developing to establish itself as a research-driven, domestic, and market-oriented industry. On the other hand, China is also emerging as a global outsourcing center for many overseas biopharmaceutical companies, especially those in the United States and Europe. The Chinese biopharmaceutical industry is actively investing in both the biologics pipeline for innovative domestic products and the bio-manufacturing infrastructure needed to commercialize these innovations. 

Anyway, as companies are continuing to grow their business in China, several issues have to be resolved, such as biogenerics versus innovative discoveries, quality and regulatory oversight, intellectual property protection, access to venture capital, and enterprise management. The other opportunity is that there are an increasing number of new drugs that are being developed by Chinese companies where the clinical trials and marketing in the US or Europe will be better handled by a Western biopharma company with regional regulatory expertise, in-place sales, and marketing resources, and, if needed, funding.

Key Developments

• In December 2018, the State Drug Administration (NMPA) has announced the approval of the list of the first domestically produced PD-1 monoclonal antibody, i.e., tripril monoclonal antibody injection that was developed by Suzhou Zhonghe Biomedical Co., Ltd. (A subsidiary of Shanghai Junshi Biosciences Co., Ltd.) used to treat local progression or metastatic melanoma after the failure of previous standard treatment.


• AMOYTOP BIOTECH, the leading manufacturer of recombinant biopharmaceutical products in China with cGMP, produces Molgramostim, Filgrastim, Oprelvekin, Interferon-alfa-2a, Interferon-alfa-2b, Interferon gamma, Interferon-2, and Somatropin, and provides bio-reagents, such as Interleukin-4, TNF, and recombinant human SOD.

Segmentation

The biopharmaceutical market in china is presented as follows:

By Company: Examples of companies in the Chinese biopharmaceutical market include Amoytop Biotech, Beijing Continent Pharmaceuticals, Fusogen, Shanghai Huaguan Biochip, Sibiono Genetech, Abbott, Roche, Pfizer, Gsk,Novartis.

By Therapeutic Area: Examples of Chinese biopharmaceutical market treating areas are Anti-infective, Cancer, Diabetes, Dementia, Depression.

Biopharmaceuticals have shown a reduction in the number of deaths because of cancer and HIV/AIDS in the past decade, which has led to an increase in the adoption of biopharmaceuticals in the global market. However, on the road to innovation, still, China has a lot of things to do, such as speeding up pharmaceutical policy reform, development of cross-border technology intermediary, R & D internationalization, accelerating the realization of the healthy China 2030 strategic.